What is USANA Health Sciences Inc's earnings per share (EPS)?

USANA Health Sciences Inc (USNA) reported diluted earnings per share of $0.58 for fiscal year 2025. This represents a -73.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

USANA Health Sciences (USNA) Financials

USNA NYSE

Trailing 12 months to July 4, 2026

Revenue $913.4M +1.6% YoY

Net Income -$22.2M -165.0% YoY

EPS (Diluted) -$1.20 -166.7% YoY

Free Cash Flow $15.9M -68.7% YoY

Market Cap $260.0M as of Oct 27, 2026

Price / Sales 0.3x on $913.4M revenue, trailing 12 months to July 4, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to July 4, 2026

Price / Book 0.5x on $526.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jul 4, 2026 Reported Aug 13, 2026 Currency USD FYE January

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the USNA SEC filings page.

USANA Health Sciences Inc (USNA) reported $913.4M in revenue over the twelve months to Jul 4, 2026, up 1.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI USNA FY2025 2026-10-22

Revenue recovered, but rising costs and inventory investment left USANA with sharply weaker profits and cash generation.

The FY2025 rebound in revenue of 8.3% coincided with a 63.4% decline in operating cash flow, showing that sales recovery did not translate into cash. Free cash flow fell from $50.9M in FY2024 to $8.5M in FY2025, indicating that weaker operating cash generation—not simply expansion spending—drove the squeeze.

Revenue rose 8.3%, but selling, general and administrative expense rose 28.1%, revealing cost growth well ahead of sales. Gross margin fell 2.8 percentage points to 78.3%, while operating margin reached only 4.0%, so the main pressure appeared below gross profit.

Liabilities were just 21.1% of assets and the current ratio was 2.2x, pointing to a relatively lightly financed balance sheet rather than debt-driven strain. Yet inventory rose 47.1% while current assets rose only 3.3%, meaning more near-term resources became tied up in stock.

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of USANA Health Sciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

USANA Health Sciences Inc has an operating margin of 4.0%, meaning the company retains $4 of operating profit per $100 of revenue. This results in a moderate score of 54/100, indicating healthy but not exceptional operating efficiency. This is down from 7.8% the prior year.

Growth

USANA Health Sciences Inc's revenue grew 8.3% year-over-year to $925.3M, a solid pace of expansion. This earns a growth score of 31/100.

Leverage

Liquidity

With a current ratio of 2.24, USANA Health Sciences Inc holds $2.24 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 65/100.

Cash Flow

USANA Health Sciences Inc has a free cash flow margin of 0.9%, earning a moderate score of 39/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

USANA Health Sciences Inc's ROE of 2.0% shows moderate profitability relative to equity, earning a score of 61/100. This is down from 7.9% the prior year.

Altman Z-Score Safe

3.54

USANA Health Sciences Inc scores 3.54, well above the 2.99 safe threshold. The largest contribution to the score comes from revenue of $925.3M against total assets of $742.9M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

USANA Health Sciences Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Cash-Backed

2.08x

For every $1 of reported earnings, USANA Health Sciences Inc generates $2.08 in operating cash flow ($22.3M OCF vs $10.8M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

44.46x

USANA Health Sciences Inc earns $44.46 in operating income for every $1 of interest expense ($37.4M vs $842K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$223.3M

YoY-5.3%

QoQ-10.8%

5Y CAGR-7.9%

10Y CAGR-1.5%

USANA Health Sciences Inc generated $223.3M in revenue in Q2 2026. This represents a decrease of 5.3% from the same quarter a year earlier. Against the prior quarter it is down 10.8%.

EBITDA

-$12.3M

YoY-150.4%

QoQ-155.6%

USANA Health Sciences Inc's EBITDA was -$12.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 150.4% from the same quarter a year earlier. Against the prior quarter it is down 155.6%.

Net Income

-$21.4M

YoY-321.5%

QoQ-384.5%

USANA Health Sciences Inc reported a net loss of $21.4M in Q2 2026. This represents a decrease of 321.5% from the same quarter a year earlier. Against the prior quarter it is down 384.5%.

EPS (Diluted)

-$1.16

YoY-323.1%

QoQ-382.9%

USANA Health Sciences Inc earned -$1.16 per diluted share (EPS) in Q2 2026. This represents a decrease of 323.1% from the same quarter a year earlier. Against the prior quarter it is down 382.9%.

Cash & Balance Sheet

Free Cash Flow

$20.2M

YoY+180.4%

QoQ+183.4%

5Y CAGR-11.7%

10Y CAGR-3.8%

USANA Health Sciences Inc generated $20.2M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 180.4% from the same quarter a year earlier. Against the prior quarter it is up 183.4%.

Cash & Debt

$168.6M

YoY+11.4%

QoQ+3.6%

5Y CAGR-8.7%

10Y CAGR+4.1%

USANA Health Sciences Inc held $168.6M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

18M

YoY+1.1%

QoQ+0.1%

5Y CAGR-1.6%

USANA Health Sciences Inc had 18M shares outstanding in Q2 2026. This represents an increase of 1.1% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

78.3%

YoY-0.4pp

QoQ+2.1pp

5Y change-4.7pp

10Y change-3.9pp

USANA Health Sciences Inc's gross margin was 78.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.1 percentage points.

Operating Margin

-9.0%

YoY-16.1pp

QoQ-14.5pp

5Y change-24.9pp

USANA Health Sciences Inc's operating margin was -9.0% in Q2 2026, reflecting core business profitability. This is down 16.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.5 percentage points.

Net Margin

-9.6%

YoY-13.7pp

QoQ-12.6pp

5Y change-20.9pp

10Y change-19.6pp

USANA Health Sciences Inc's net profit margin was -9.6% in Q2 2026, showing the share of revenue converted to profit. This is down 13.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 12.6 percentage points.

Return on Equity

-4.1%

YoY-5.9pp

QoQ-5.4pp

5Y change-13.2pp

10Y change-13.5pp

USANA Health Sciences Inc's quarterly ROE was -4.1% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.4 percentage points.

Capital Allocation

Share Buybacks

YoY-100.0%

QoQn/m

USANA Health Sciences Inc repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Capital Expenditures

$3.2M

YoY-37.2%

QoQ+19.3%

5Y CAGR+15.3%

10Y CAGR-3.9%

USANA Health Sciences Inc invested $3.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 37.2% from the same quarter a year earlier. Against the prior quarter it is up 19.3%.

R&D Spending

Not reported for Q2 2026.

USNA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

USNA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$913.4M	$925.3M+8.3%	$854.5M-7.2%	$921.0M-7.8%	$998.6M-15.8%	$1.2B+4.6%	$1.1B+7.0%	$1.1B-10.8%	$1.2B+13.6%	$1.0B+4.1%	$1.0B+9.5%	$918.5M+16.2%	$790.5M+10.1%	$718.2M+10.7%	$648.7M+11.5%	$581.9M
Cost of Revenue	$206.0M	$200.9M+24.6%	$161.2M-8.8%	$176.7M-8.9%	$193.9M-11.0%	$217.9M+4.2%	$209.1M+11.5%	$187.5M-6.6%	$200.7M+11.9%	$179.4M-0.4%	$180.2M+12.8%	$159.7M+13.4%	$140.8M+10.5%	$127.4M+10.0%	$115.8M+13.9%	$101.7M
Gross Profit	$707.4M	$724.4M+4.5%	$693.3M-6.9%	$744.3M-7.5%	$804.7M-16.9%	$968.6M+4.6%	$925.5M+6.0%	$873.4M-11.6%	$988.5M+13.9%	$867.9M+5.1%	$825.9M+8.8%	$758.8M+16.8%	$649.7M+10.0%	$590.7M+10.8%	$532.9M+11.0%	$480.2M
R&D Expenses	N/A	$10.7M-7.6%	$11.6M+1.1%	$11.4M-1.0%	$11.6M+4.1%	$11.1M+4.5%	$10.6M+3.6%	$10.3M+0.2%	$10.2M+14.4%	$9.0M+1.2%	$8.8M+37.7%	$6.4M+25.2%	$5.1M+0.9%	$5.1M+9.0%	$4.7M+14.6%	$4.1M
SG&A Expenses	$334.6M	$337.4M+28.1%	$263.3M+2.4%	$257.0M-2.0%	$262.3M-6.0%	$279.1M+6.9%	$261.2M-2.4%	$267.7M-2.7%	$275.1M+3.8%	$265.1M+13.2%	$234.2M+12.1%	$209.0M+13.3%	$184.5M+11.0%	$166.2M+7.8%	$154.2M+12.5%	$137.1M
Operating Income	-$1.1M	$37.4M-43.6%	$66.3M-28.7%	$93.1M-13.5%	$107.6M-36.8%	$170.2M-3.6%	$176.5M+20.7%	$146.2M-22.4%	$188.4M+42.1%	$132.5M-4.4%	$138.6M-2.1%	$141.7M+22.0%	$116.1M-0.5%	$116.7M+18.9%	$98.2M+27.1%	$77.3M
EBITDA	N/A	$70.0M-13.4%	$80.9M-23.6%	$105.8M-12.6%	$121.0M-34.0%	$183.2M-3.7%	$190.2M+18.2%	$160.9M-21.6%	$205.2M+38.1%	$148.6M-2.3%	$152.1M+0.3%	$151.6M+21.4%	$124.9M-0.7%	$125.8M+17.5%	$107.0M+24.8%	$85.7M
Interest Expense	$412K	$842K+199.6%	$281K+7.3%	$262K+36.5%	$192K+236.8%	$57K-88.8%	$507K+668.2%	$66K+83.3%	$36K-21.7%	$46K-89.6%	$444K+2860.0%	$15K-88.4%	$129K+12800.0%	$1K-95.0%	$20K+122.2%	$9K
Income Tax	$31.8M	$30.1M-12.4%	$34.3M-11.3%	$38.7M-1.5%	$39.3M-27.5%	$54.1M+1.6%	$53.3M+6.6%	$50.0M-23.5%	$65.3M-9.5%	$72.1M+87.2%	$38.5M-19.6%	$47.9M+22.8%	$39.0M+3.9%	$37.6M+17.4%	$32.0M+19.7%	$26.7M
Net Income	-$22.2M	$10.8M-74.4%	$42.0M-34.1%	$63.8M-8.0%	$69.3M-40.5%	$116.5M-6.5%	$124.7M+24.0%	$100.5M-20.4%	$126.2M+101.8%	$62.5M-37.5%	$100.0M+5.7%	$94.7M+23.5%	$76.6M-3.0%	$79.0M+19.0%	$66.4M+30.9%	$50.8M
EPS (Basic)	N/A	$0.58-73.6%	$2.20-33.5%	$3.31-8.1%	$3.60-37.7%	$5.78-1.9%	$5.89+32.7%	$4.44-15.3%	$5.24+103.9%	$2.57-37.9%	$4.14	$3.72+28.3%	$2.90	$5.77+26.3%	$4.57+38.5%	$3.30
EPS (Diluted)	-$1.20	$0.58-73.5%	$2.19-33.6%	$3.30-8.1%	$3.59-37.3%	$5.73-2.2%	$5.86+32.9%	$4.41-13.9%	$5.12+102.4%	$2.53-36.6%	$3.99	$3.59+28.2%	$2.80	$5.56+24.9%	$4.45+36.5%	$3.26
Diluted Shares (Avg)	N/A	19M-3.1%	19M-0.9%	19M+0.2%	19M-5.1%	20M-4.3%	21M-6.8%	23M-7.4%	25M-0.3%	25M-1.4%	25M	26M-3.7%	27M	14M-4.8%	15M-4.2%	16M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$223.3M-5.3%	$250.2M+0.3%	$226.2M+5.9%	$213.7M+6.7%	$235.8M+10.8%	$249.5M+9.5%	$213.6M-3.4%	$200.2M-6.2%
Cost of Revenue	$48.3M-3.7%	$59.4M+13.3%	$49.4M+28.2%	$48.8M+24.3%	$50.2M+24.4%	$52.4M+21.8%	$38.6M-8.9%	$39.3M-7.7%
Gross Profit	$174.9M-5.8%	$190.8M-3.2%	$176.8M+1.0%	$164.9M+2.4%	$185.7M+7.6%	$197.1M+6.7%	$175.1M-2.1%	$161.0M-5.8%
SG&A Expenses	$82.3M+0.5%	$88.3M-3.5%	$78.1M+6.5%	$85.9M+40.2%	$81.9M+27.3%	$91.4M+42.2%	$73.3M+25.0%	$61.3M-3.2%
Operating Income	-$20.0M-219.6%	$13.9M-11.5%	$3.8M-53.5%	$1.2M-92.2%	$16.7M-6.3%	$15.7M-36.5%	$8.2M-66.1%	$15.6M-11.4%
EBITDA	-$12.3M-150.4%	$22.2M-7.7%	$12.4M+1.4%	$9.1M-52.3%	$24.5M+13.0%	$24.0M-13.7%	$12.2M-55.0%	$19.2M-8.2%
Interest Expense	$0-100.0%	$240K-41.6%	$123K-4.7%	$49K0.0%	$259K+407.8%	$411K+690.4%	$129K-11.0%	$49K+14.0%
Income Tax	$9.1M+8.1%	$8.5M+14.2%	$5.8M-2.9%	$8.5M+5.7%	$8.4M-14.3%	$7.4M-29.6%	$5.9M-39.6%	$8.0M-12.9%
Net Income	-$21.4M-321.5%	$7.5M-20.1%	-$1.8M-139.9%	-$6.5M-161.5%	$9.7M-7.4%	$9.4M-43.1%	$4.5M-73.4%	$10.6M-6.5%
EPS (Basic)	-$1.16-323.1%	$0.41-16.3%	-$0.09-139.1%	-$0.36-164.3%	$0.52-5.5%	$0.49-43.0%	$0.23-73.6%	$0.56-5.1%
EPS (Diluted)	-$1.16-323.1%	$0.41-16.3%	-$0.09-139.1%	-$0.36-164.3%	$0.52-3.7%	$0.49-43.0%	$0.23-73.6%	$0.56-5.1%
Diluted Shares (Avg)	18M-0.3%	18M-3.5%	N/A	18M-4.1%	19M-3.3%	19M-1.1%	N/A	19M-1.5%

Not reported in any period shown, so not listed: R&D Expenses.

USNA Balance Sheet

USNA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$742.9M-0.7%	$748.2M+18.2%	$632.8M+6.1%	$596.5M+3.3%	$577.7M-9.9%	$640.9M+24.0%	$516.9M-6.8%	$554.5M+6.8%	$519.3M+10.3%	$470.6M+11.2%	$423.2M+20.7%	$350.6M-4.9%	$368.5M+37.8%	$267.4M+9.3%	$244.5M
Current Assets	$288.4M+3.3%	$279.2M-33.2%	$417.7M+8.7%	$384.4M+5.3%	$365.1M-14.1%	$425.3M+29.2%	$329.3M-16.1%	$392.3M+15.3%	$340.2M+22.4%	$277.9M+13.8%	$244.3M+27.9%	$190.9M-16.6%	$229.0M+72.8%	$132.5M+25.0%	$106.1M
Cash & Equivalents	$158.4M-12.9%	$181.8M-45.0%	$330.4M+14.6%	$288.4M+20.3%	$239.8M-23.1%	$311.9M+32.8%	$234.8M+9.6%	$214.3M-13.3%	$247.1M+40.6%	$175.8M+22.7%	$143.2M+28.9%	$111.1M-19.1%	$137.3M+93.9%	$70.8M+40.7%	$50.4M
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$63.5Mn/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$8.6Mn/m	$0n/m	$0
Inventory	$102.6M+47.1%	$69.7M+13.5%	$61.5M-8.4%	$67.1M-31.8%	$98.3M0.0%	$98.3M+42.7%	$68.9M-15.9%	$81.9M+30.2%	$62.9M-2.9%	$64.8M-2.0%	$66.1M+46.1%	$45.2M-4.2%	$47.2M+29.5%	$36.5M-1.3%	$37.0M
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$138.0M-4.3%	$144.2M+743.0%	$17.1M-1.5%	$17.4M-1.7%	$17.7M+1.7%	$17.4M+4.4%	$16.6M-1.1%	$16.8M-3.5%	$17.4M+4.2%	$16.7M-4.1%	$17.4M-2.8%	$17.9M-1.7%	$18.2M+2.0%	$17.9M+0.8%	$17.7M
Total Liabilities	$156.6M-3.2%	$161.9M+19.4%	$135.6M-16.4%	$162.1M-11.2%	$182.6M-8.3%	$199.2M+20.6%	$165.2M+1.2%	$163.3M+4.7%	$156.1M+7.4%	$145.4M+2.1%	$142.4M+18.2%	$120.4M+11.6%	$107.9M+32.0%	$81.8M+15.9%	$70.6M
Current Liabilities	$128.6M-7.9%	$139.6M+17.5%	$118.8M-17.4%	$143.8M-10.5%	$160.8M-4.3%	$168.1M+23.5%	$136.1M-8.5%	$148.7M+5.3%	$141.2M+1.9%	$138.5M+5.4%	$131.4M+20.9%	$108.7M+13.4%	$95.9M+35.3%	$70.8M+18.7%	$59.7M
Non-Current Liabilities	$28.1M+26.3%	$22.2M+33.1%	$16.7M-8.4%	$18.2M-16.4%	$21.8M-30.0%	$31.2M+7.0%	$29.1M+99.1%	$14.6M-1.6%	$14.9M+116.7%	$6.9M-37.4%	$11.0M-6.3%	$11.7M-3.0%	$12.1M+10.4%	$10.9M+0.4%	$10.9M
Total Equity	$533.1M+0.2%	$532.1M+7.0%	$497.2M+14.4%	$434.5M+10.0%	$395.1M-10.5%	$441.6M+25.6%	$351.7M-10.1%	$391.1M+7.7%	$363.2M+11.7%	$325.3M+15.8%	$280.9M+22.0%	$230.2M-11.7%	$260.5M+40.4%	$185.6M+6.7%	$173.9M
Retained Earnings	$465.7M-2.8%	$478.9M+7.6%	$445.2M+13.7%	$391.6M+13.6%	$344.6M-10.0%	$382.8M+25.0%	$306.1M-7.1%	$329.5M+14.4%	$288.1M+8.5%	$265.4M+23.5%	$214.9M+29.1%	$166.4M-16.8%	$200.0M+48.4%	$134.8M+13.5%	$118.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$703.2M-4.3%	$739.0M-1.0%	$742.9M-0.7%	$726.6M+8.2%	$734.5M+16.3%	$746.6M+18.6%	$748.2M+18.2%	$671.3M+11.7%
Current Assets	$281.1M+7.3%	$294.2M+4.6%	$288.4M+3.3%	$264.1M-41.5%	$261.9M-37.5%	$281.4M-33.2%	$279.2M-33.2%	$451.2M+15.6%
Cash & Equivalents	$168.6M+11.4%	$162.8M-9.4%	$158.4M-12.9%	$145.3M-60.2%	$151.3M-54.5%	$179.6M-45.3%	$181.8M-45.0%	$364.9M+18.8%
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Inventory	$86.3M+3.7%	$96.4M+31.0%	$102.6M+47.1%	$90.8M+41.9%	$83.3M+34.7%	$73.6M+20.8%	$69.7M+13.5%	$64.0M+6.5%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Goodwill	$109.1M-24.3%	$138.1M-4.2%	$138.0M-4.3%	$144.3M+739.1%	$144.2M+756.6%	$144.2M+753.3%	$144.2M+743.0%	$17.2M+2.4%
Total Liabilities	$132.2M-11.2%	$144.2M-11.4%	$156.6M-3.2%	$145.0M+4.9%	$149.0M+25.0%	$162.7M+25.9%	$161.9M+19.4%	$138.2M+5.7%
Current Liabilities	$105.7M-13.1%	$117.2M-14.7%	$128.6M-7.9%	$118.7M+3.4%	$121.6M+17.1%	$137.4M+22.0%	$139.6M+17.5%	$114.8M+2.0%
Non-Current Liabilities	$26.6M-2.9%	$26.9M+6.3%	$28.1M+26.3%	$26.4M+12.5%	$27.3M+78.5%	$25.3M+52.1%	$22.2M+33.1%	$23.4M+28.8%
Total Equity	$526.3M-0.9%	$543.5M+2.6%	$533.1M+0.2%	$528.1M-0.9%	$531.1M+3.7%	$529.8M+6.0%	$532.1M+7.0%	$533.1M+13.3%
Retained Earnings	$451.9M-4.7%	$473.2M-0.9%	$465.7M-2.8%	$467.5M-1.5%	$474.0M+2.2%	$477.6M+5.3%	$478.9M+7.6%	$474.5M+10.7%

Not reported in any period shown, so not listed: Accounts Receivable, Long-Term Debt.

USNA Cash Flow Statement

USNA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$27.7M	$22.3M-63.4%	$61.0M-13.7%	$70.6M-32.0%	$103.9M-14.3%	$121.2M-24.4%	$160.4M+26.6%	$126.7M-16.7%	$152.1M+22.9%	$123.8M-9.6%	$136.9M+22.8%	$111.5M+6.0%	$105.2M+6.4%	$98.9M+6.6%	$92.8M+32.4%	$70.1M
Depreciation & Amortization	N/A	$32.6M+124.0%	$14.5M+14.5%	$12.7M-5.2%	$13.4M+2.7%	$13.0M-5.2%	$13.7M-6.8%	$14.7M-12.5%	$16.8M+4.5%	$16.1M+19.5%	$13.5M+35.1%	$10.0M+13.3%	$8.8M-2.6%	$9.0M+2.5%	$8.8M+4.2%	$8.5M
Stock-Based Compensation	N/A	$13.8M-5.0%	$14.6M-0.3%	$14.6M+9.5%	$13.3M-6.8%	$14.3M-0.7%	$14.4M-7.4%	$15.5M+3.9%	$15.0M-3.4%	$15.5M-6.4%	$16.5M+49.3%	$11.1M+13.0%	$9.8M+28.6%	$7.6M-25.3%	$10.2M-3.2%	$10.5M
Capital Expenditures	$11.8M	$13.8M+37.2%	$10.1M-30.5%	$14.5M+39.4%	$10.4M-18.5%	$12.8M-15.4%	$15.1M-8.9%	$16.6M+44.9%	$11.4M-13.5%	$13.2M-59.6%	$32.7M+37.8%	$23.7M+16.2%	$20.4M+153.6%	$8.1M-4.5%	$8.4M-20.8%	$10.6M
Free Cash Flow	$15.9M	$8.5M-83.3%	$50.9M-9.3%	$56.1M-40.0%	$93.5M-13.8%	$108.5M-25.4%	$145.3M+31.9%	$110.2M-21.7%	$140.7M+27.3%	$110.6M+6.1%	$104.2M+18.8%	$87.7M+3.5%	$84.8M-6.7%	$90.8M+7.7%	$84.4M+41.9%	$59.5M
Investing Cash Flow	-$8.7M	-$10.1Mn/m	-$213.1Mn/m	-$12.0Mn/m	-$12.4Mn/m	-$14.2Mn/m	-$34.0M-171.5%	$47.5Mn/m	-$69.0Mn/m	-$12.9Mn/m	-$31.9Mn/m	-$25.1Mn/m	-$16.3Mn/m	-$21.6Mn/m	-$8.3Mn/m	-$10.6M
Financing Cash Flow	-$5.2M	-$40.6M-525.0%	$9.6Mn/m	-$14.2Mn/m	-$30.1Mn/m	-$181.4Mn/m	-$59.4Mn/m	-$152.1Mn/m	-$105.3Mn/m	-$50.3Mn/m	-$64.9Mn/m	-$49.2Mn/m	-$113.0Mn/m	-$10.2Mn/m	-$64.5Mn/m	-$33.4M
Share Buybacks	$0	$27.5M+191.3%	$9.4M-18.6%	$11.6M-54.3%	$25.4M-85.7%	$177.8M+211.8%	$57.0M-62.0%	$150.0M+42.3%	$105.4M+110.8%	$50.0M-22.6%	$64.6M+5.6%	$61.2M-55.9%	$138.8M+667.6%	$18.1M-73.5%	$68.3M+104.1%	$33.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$23.3M+90.9%	$9.8M-37.0%	-$3.4M-158.6%	-$2.0M-106.6%	$12.2M+52.9%	$15.5M-12.4%	$5.8M-77.8%	$29.5M+32.8%
Depreciation & Amortization	$7.7M-0.9%	$8.3M-0.7%	$8.6M+114.1%	$7.9M+121.9%	$7.7M+103.1%	$8.3M+164.1%	$4.0M+37.3%	$3.6M+9.1%
Stock-Based Compensation	N/A	$3.5M+19.9%	N/A	N/A	N/A	$2.9M-21.5%	N/A	N/A
Capital Expenditures	$3.2M-37.2%	$2.6M-5.6%	$2.8M+55.1%	$3.2M+33.3%	$5.0M+88.2%	$2.8M-12.4%	$1.8M-75.4%	$2.4M+65.0%
Free Cash Flow	$20.2M+180.4%	$7.1M-43.9%	-$6.2M-255.3%	-$5.2M-119.0%	$7.2M+35.2%	$12.7M-12.4%	$4.0M-78.7%	$27.1M+30.6%
Investing Cash Flow	-$4.1Mn/m	-$2.6Mn/m	$1.1Mn/m	-$3.2Mn/m	-$4.2Mn/m	-$3.9Mn/m	-$205.1Mn/m	-$2.3Mn/m
Financing Cash Flow	-$14.0Mn/m	-$3.6Mn/m	$13.5M-41.3%	-$979Kn/m	-$38.6Mn/m	-$14.5Mn/m	$22.9M+3384.8%	-$78Kn/m
Share Buybacks	$0-100.0%	$0-100.0%	$0n/m	$0n/m	$15.2Mn/m	$12.3M+30.2%	$0n/m	$0-100.0%

Not reported in any period shown, so not listed: Dividends Paid.

USNA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

USNA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	78.3%-2.8pp	81.1%+0.3pp	80.8%+0.2pp	80.6%-1.1pp	81.6%+0.1pp	81.6%-0.8pp	82.3%-0.8pp	83.1%+0.3pp	82.9%+0.8pp	82.1%-0.5pp	82.6%+0.4pp	82.2%-0.1pp	82.3%+0.1pp	82.2%-0.4pp	82.5%
Operating Margin	4.0%-3.7pp	7.8%-2.3pp	10.1%-0.7pp	10.8%-3.6pp	14.3%-1.2pp	15.6%+1.8pp	13.8%-2.1pp	15.8%+3.2pp	12.7%-1.1pp	13.8%-1.6pp	15.4%+0.7pp	14.7%-1.6pp	16.3%+1.1pp	15.1%+1.8pp	13.3%
Net Margin	1.2%-3.8pp	4.9%-2.0pp	6.9%0.0pp	6.9%-2.9pp	9.8%-1.2pp	11.0%+1.5pp	9.5%-1.1pp	10.6%+4.6pp	6.0%-4.0pp	9.9%-0.4pp	10.3%+0.6pp	9.7%-1.3pp	11.0%+0.8pp	10.2%+1.5pp	8.7%
Return on Equity	2.0%-5.9pp	7.9%-4.9pp	12.8%-3.1pp	16.0%-13.5pp	29.5%+1.3pp	28.2%-0.4pp	28.6%-3.7pp	32.3%+15.0pp	17.2%-13.5pp	30.8%-3.0pp	33.7%+0.4pp	33.3%+3.0pp	30.3%-5.5pp	35.8%+6.6pp	29.2%
Return on Assets	1.5%-4.2pp	5.6%-4.5pp	10.1%-1.6pp	11.6%-8.5pp	20.2%+0.7pp	19.4%0.0pp	19.4%-3.3pp	22.8%+10.7pp	12.0%-9.2pp	21.3%-1.1pp	22.4%+0.5pp	21.9%+0.4pp	21.4%-3.4pp	24.9%+4.1pp	20.8%
Current Ratio	2.24+0.2x	2.00-1.5x	3.52+0.8x	2.67+0.4x	2.27-0.3x	2.53+0.1x	2.42-0.2x	2.64+0.2x	2.41+0.4x	2.01+0.1x	1.86+0.1x	1.76-0.6x	2.39+0.5x	1.87+0.1x	1.78
Liabilities-to-Equity	0.290.0x	0.300.0x	0.27-0.1x	0.37-0.1x	0.460.0x	0.450.0x	0.47+0.1x	0.420.0x	0.430.0x	0.45-0.1x	0.510.0x	0.52+0.1x	0.410.0x	0.440.0x	0.41
Asset Turnover	1.25+0.1x	1.14-0.3x	1.46-0.2x	1.67-0.4x	2.05+0.3x	1.77-0.3x	2.05-0.1x	2.14+0.1x	2.02-0.1x	2.140.0x	2.17-0.1x	2.25+0.3x	1.95-0.5x	2.430.0x	2.38
FCF Margin	0.9%-5.0pp	6.0%-0.1pp	6.1%-3.3pp	9.4%+0.2pp	9.1%-3.7pp	12.8%+2.4pp	10.4%-1.4pp	11.8%+1.3pp	10.6%+0.2pp	10.4%+0.8pp	9.6%-1.2pp	10.7%-1.9pp	12.7%-0.4pp	13.0%+2.8pp	10.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	78.3%-0.4pp	76.3%-2.7pp	78.2%-3.8pp	77.1%-3.2pp	78.7%-2.3pp	79.0%-2.1pp	82.0%+1.1pp	80.4%+0.3pp
Operating Margin	-9.0%-16.1pp	5.5%-0.7pp	1.7%-2.1pp	0.6%-7.2pp	7.1%-1.3pp	6.3%-4.5pp	3.8%-7.1pp	7.8%-0.5pp
Net Margin	-9.6%-13.7pp	3.0%-0.8pp	-0.8%-2.9pp	-3.0%-8.3pp	4.1%-0.8pp	3.8%-3.5pp	2.1%-5.5pp	5.3%0.0pp
Return on Equity	-4.1%-5.9pp	1.4%-0.4pp	-0.3%-1.2pp	-1.2%-3.2pp	1.8%-0.2pp	1.8%-1.5pp	0.8%-2.5pp	2.0%-0.4pp
Return on Assets	-3.0%-4.3pp	1.0%-0.2pp	-0.2%-0.8pp	-0.9%-2.5pp	1.3%-0.3pp	1.3%-1.4pp	0.6%-2.0pp	1.6%-0.3pp
Current Ratio	2.66+0.5x	2.51+0.5x	2.24+0.2x	2.23-1.7x	2.15-1.9x	2.05-1.7x	2.00-1.5x	3.93+0.5x
Liabilities-to-Equity	0.250.0x	0.270.0x	0.290.0x	0.270.0x	0.280.0x	0.310.0x	0.300.0x	0.260.0x
Asset Turnover	0.320.0x	0.340.0x	0.300.0x	0.290.0x	0.320.0x	0.330.0x	0.29-0.1x	0.30-0.1x
FCF Margin	9.0%+6.0pp	2.8%-2.2pp	-2.7%-4.6pp	-2.4%-16.0pp	3.0%+0.5pp	5.1%-1.3pp	1.9%-6.6pp	13.6%+3.8pp

Not reported in any period shown, so not listed: Debt-to-Equity.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
USANA Health Sciences Inc USNA	FY2025	$925.3M	$10.8M	1.2%	$260.0M	53/100
Oatly Group AB OTLY	FY2025	$862.5M	-$152.8M	-17.7%	$375.0M	18/100
Westrock Coffee Company WEST	FY2025	$1.2B	-$90.4M	-7.6%	$943.1M	25/100
Lifeway Foods Inc LWAY	FY2025	$212.5M	$13.9M	6.5%	$350.8M	62/100
Seneca Foods Corp SENEB	FY2026	N/A	$114.7M	N/A	$1.1B	—
John B. Sanfilippo & SON JBSS	FY2026	$1.2B	$61.9M	5.3%	$784.7M	61/100

Where USANA Health Sciences Inc Ranks

Frequently Asked Questions

What is USANA Health Sciences Inc's annual revenue?

USANA Health Sciences Inc (USNA) reported $925.3M in total revenue for fiscal year 2025. This represents a 8.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is USANA Health Sciences Inc's revenue growing?

USANA Health Sciences Inc (USNA) revenue grew by 8.3% year-over-year, from $854.5M to $925.3M in fiscal year 2025.

Is USANA Health Sciences Inc profitable?

No, USANA Health Sciences Inc (USNA) reported a net loss of $22.2M over the trailing 12 months to July 4, 2026. In fiscal year 2025 it reported a net income of $10.8M, with a net profit margin of 1.2%.

What is USANA Health Sciences Inc's EBITDA?

USANA Health Sciences Inc (USNA) had EBITDA of $70.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is USANA Health Sciences Inc's gross margin?

USANA Health Sciences Inc (USNA) had a gross margin of 78.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is USANA Health Sciences Inc's operating margin?

USANA Health Sciences Inc (USNA) had an operating margin of 4.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is USANA Health Sciences Inc's net profit margin?

USANA Health Sciences Inc (USNA) had a net profit margin of 1.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is USANA Health Sciences Inc's return on equity (ROE)?

USANA Health Sciences Inc (USNA) has a return on equity of 2.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is USANA Health Sciences Inc's free cash flow?

USANA Health Sciences Inc (USNA) generated $8.5M in free cash flow during fiscal year 2025. This represents a -83.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is USANA Health Sciences Inc's operating cash flow?

USANA Health Sciences Inc (USNA) generated $22.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are USANA Health Sciences Inc's total assets?

USANA Health Sciences Inc (USNA) had $742.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are USANA Health Sciences Inc's capital expenditures?

USANA Health Sciences Inc (USNA) invested $13.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does USANA Health Sciences Inc spend on research and development?

USANA Health Sciences Inc (USNA) invested $10.7M in research and development during fiscal year 2025.

Does USANA Health Sciences Inc buy back shares?

Yes, USANA Health Sciences Inc (USNA) spent $27.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does USANA Health Sciences Inc have outstanding?

USANA Health Sciences Inc (USNA) had 18M shares outstanding as of fiscal year 2025.

What is USANA Health Sciences Inc's current ratio?

USANA Health Sciences Inc (USNA) had a current ratio of 2.24 as of fiscal year 2025, which is generally considered healthy.

What is USANA Health Sciences Inc's liabilities-to-equity ratio?

USANA Health Sciences Inc (USNA) had a liabilities-to-equity ratio of 0.29 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is USANA Health Sciences Inc's return on assets (ROA)?

USANA Health Sciences Inc (USNA) had a return on assets of 1.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is USANA Health Sciences Inc's P/E ratio?

USANA Health Sciences Inc (USNA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to July 4, 2026). The market capitalization is $260.0M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is USANA Health Sciences Inc's price-to-sales ratio?

USANA Health Sciences Inc (USNA) trades at 0.3x sales, its market capitalization divided by $913.4M revenue, trailing 12 months to July 4, 2026. The market capitalization is $260.0M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is USANA Health Sciences Inc's Altman Z-Score?

USANA Health Sciences Inc (USNA) has an Altman Z-Score of 3.54, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is USANA Health Sciences Inc's Piotroski F-Score?

USANA Health Sciences Inc (USNA) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are USANA Health Sciences Inc's earnings high quality?

USANA Health Sciences Inc (USNA) has an earnings quality ratio of 2.08x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can USANA Health Sciences Inc cover its interest payments?

USANA Health Sciences Inc (USNA) has an interest coverage ratio of 44.46x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is USANA Health Sciences Inc?

USANA Health Sciences Inc (USNA) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.